These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36210541)

  • 41. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.
    Cynamon MH; Klemens SP; Sharpe CA; Chase S
    Antimicrob Agents Chemother; 1999 May; 43(5):1189-91. PubMed ID: 10223934
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcomes of pulmonary tuberculosis in patients with discordant phenotypic isoniazid resistance testing.
    Kim S; Lee H; Park HY; Jeon K; Huh HJ; Lee NY; Jeong BH
    Respir Med; 2017 Dec; 133():6-11. PubMed ID: 29173450
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance.
    Stagg HR; Bothamley GH; Davidson JA; Kunst H; Lalor MK; Lipman MC; Loutet MG; Lozewicz S; Mohiyuddin T; Abbara A; Alexander E; Booth H; Creer DD; Harris RJ; Kon OM; Loebinger MR; McHugh TD; Milburn HJ; Palchaudhuri P; Phillips PPJ; Schmok E; Taylor L; Abubakar I;
    Eur Respir J; 2019 Oct; 54(4):. PubMed ID: 31371444
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug-resistance of Mycobacterium tuberculosis in Patras, Greece.
    Trakada G; Tsiamita M; Spiropoulos K
    Monaldi Arch Chest Dis; 2004; 61(1):65-70. PubMed ID: 15366340
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis.
    De Logu A; Onnis V; Saddi B; Congiu C; Schivo ML; Cocco MT
    J Antimicrob Chemother; 2002 Feb; 49(2):275-82. PubMed ID: 11815568
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clonal expansion of Mycobacterium tuberculosis isolates and coexisting drug resistance in patients newly diagnosed with pulmonary tuberculosis in Hanoi, Vietnam.
    Hung NV; Ando H; Thuy TT; Kuwahara T; Hang NT; Sakurada S; Thuong PH; Lien LT; Keicho N
    BMC Res Notes; 2013 Nov; 6():444. PubMed ID: 24188178
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Management and treatment difficulties of multi-drug resistant pulmonary tuberculosis in a pediatric case].
    Hançerli Törün S; Acar EM; Somer A; Erköse G; Şatana D; Bayramoğlu Z; Çalışkan E; Kılıçaslan Z
    Mikrobiyol Bul; 2018 Jan; 52(1):89-95. PubMed ID: 29642833
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Prevalence and transmission of pyrazinamide-resistant
    Liu BB; Hu PL; Chen ZH; Yi SL; Zhang XP; Tan YH
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Jul; 45(7):677-685. PubMed ID: 35768376
    [No Abstract]   [Full Text] [Related]  

  • 49. Mycobacterium resistance to antimycobacterial reagent.
    Aghandous R; Zouhdi M; Zizi M; Errami M; Idrissi L
    Therapie; 1999; 54(5):623-5. PubMed ID: 10667100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Blood agar validation for susceptibility testing of isoniazid, rifampicin, ethambutol, and streptomycin to Mycobacterium tuberculosis isolates.
    Coban AY
    PLoS One; 2013; 8(2):e55370. PubMed ID: 23405140
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protein binding investigation of first-line and second-line antituberculosis drugs.
    Fage D; Aalhoul F; Cotton F
    Int J Antimicrob Agents; 2023 Dec; 62(6):106999. PubMed ID: 37838149
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro activity of ciprofloxacin in combination with standard antituberculous drugs against mycobacterium tuberculosis.
    Uttley AH; Collins CH
    Tubercle; 1988 Sep; 69(3):193-5. PubMed ID: 3151140
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Application of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) in the detection of drug resistance of Mycobacterium tuberculosis in re-treated patients.
    Shi J; He G; Ning H; Wu L; Wu Z; Ye X; Qiu C; Jiang X
    Tuberculosis (Edinb); 2022 Jul; 135():102209. PubMed ID: 35550524
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of tuberculosis. The Mitchell lecture 1979.
    Mitchison DA
    J R Coll Physicians Lond; 1980 Apr; 14(2):91-5, 98-9. PubMed ID: 6767845
    [No Abstract]   [Full Text] [Related]  

  • 55. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report.
    Am Rev Respir Dis; 1978 Aug; 118(2):219-28. PubMed ID: 100029
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
    Almeida D; Nuermberger E; Tasneen R; Rosenthal I; Tyagi S; Williams K; Peloquin C; Grosset J
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug-resistant tuberculosis in Budapest.
    Fodor T; Vadász I; Lõrinczi I
    Int J Tuberc Lung Dis; 1998 Sep; 2(9):732-5. PubMed ID: 9755927
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.
    Durand F; Jebrak G; Pessayre D; Fournier M; Bernuau J
    Drug Saf; 1996 Dec; 15(6):394-405. PubMed ID: 8968694
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [A case of tuberculosis pleuritis developing contralateral pleural effusion during anti-tuberculosis chemotherapy, falling into chronic respiratory failure].
    Itoh Y; Ishiguchi T; Higashimoto Y; Fujimoto H; Ohata M; Itoh H; Nishiyama A; Okamura K; Ono H; Kawabe K; Ueda A; Suruda T
    Kekkaku; 2002 Jul; 77(7):527-31. PubMed ID: 12187817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.